Company Description
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer.
Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Benjamin Zeskind |
Contact Details
Address: 245 Main Street, Second Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617 500 8080 |
| Website | immuneering.com |
Stock Details
| Ticker Symbol | IMRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001790340 |
| CUSIP Number | 45254E107 |
| ISIN Number | US45254E1073 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Robert J. Carpenter M.B.A., M.S. | Co-Founder and Chair Emeritus |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Michael D. Bookman J.D. | Chief Legal Officer and Secretary |
| Mallory Morales CPA | Senior Vice President of Finance, Chief Accounting Officer and Treasurer |
| Paula George CPA | Director of Accounting and Operations and Assistant Corporate Controller |
| Courtney Dugan | Vice President and Head of Investor Relations and Corporate Communications |
| Leah R. Neufeld | Chief People Officer |
| Dr. Peter King Ph.D. | Head of Discovery and Vice President |
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology and Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 20, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2026 | 10-K | Annual Report |
| Mar 6, 2026 | 8-K | Current Report |
| Jan 22, 2026 | SCHEDULE 13G/A | Filing |
| Jan 15, 2026 | SCHEDULE 13G/A | Filing |
| Jan 7, 2026 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Oct 21, 2025 | SCHEDULE 13G | Filing |